Get to know our clinical trials
Clinical trial of the genetic vaccine Nous-209 for the treatment of solid tumors with microsatellite instability.
THE OBJECTIVE OF THIS CLINICAL RESEARCH STUDY IS TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNE RESPONSE AND PRELIMINARY EVIDENCE OF ANTITUMOR ACTIVITY OF THE POLYVALENT GENETIC VACCINE NOUS-209 (GAD20-209-FSP PREPARATION AND MVA-209-FSP BOOSTER) AND PEMBROLIZUMAB. PEMBROLIZUMAB IS AUTHORIZED BY THE US FOOD AND DRUG ADMINISTRATION (FDA) AND THE EUROPEAN MEDICINES AGENCY (EMA) UNDER THE TRADE NAME KEYTRUDA®.
Technical Summary
- Code EudraCT: 2021-002823-40
- Protocol number: NOUS-209-01
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.